Mark D. McKee

5.3k total citations · 3 hit papers
46 papers, 2.6k citations indexed

About

Mark D. McKee is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark D. McKee has authored 46 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark D. McKee's work include PARP inhibition in cancer therapy (16 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (7 papers). Mark D. McKee is often cited by papers focused on PARP inhibition in cancer therapy (16 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (7 papers). Mark D. McKee collaborates with scholars based in United States, Russia and Germany. Mark D. McKee's co-authors include Amy Peterson, Yuru Meng, Yuanyuan Zha, Helena Harlin, Maria Tretiakova, Craig L. Slingluff, Thomas F. Gajewski, Danielle Sullivan, Michael I. Nishimura and Jiang Qian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Mark D. McKee

44 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

2009 872 citations Helena Harlin, Yuru Meng et al. Cancer Research profile →
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

2018 516 citations Mark D. McKee, Danielle Sullivan et al. profile →
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

2014 465 citations Călin Cainap, Shukui Qin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark D. McKee United States	18	1.6k	951	744	490	453	46	2.6k
Jeffrey J. Wallin United States	28	1.2k 0.8×	1.1k 1.2×	829 1.1×	228 0.5×	240 0.5×	60	2.8k
Ann Cleverly United States	25	1.5k 1.0×	530 0.6×	1.3k 1.8×	428 0.9×	193 0.4×	54	2.6k
Joe Yeong Singapore	26	1.5k 0.9×	1.1k 1.2×	763 1.0×	426 0.9×	234 0.5×	94	2.7k
Camilla Pilati France	19	1.1k 0.7×	340 0.4×	1.1k 1.5×	617 1.3×	542 1.2×	32	2.7k
Justin L. Ricker United States	23	1.2k 0.7×	558 0.6×	2.5k 3.3×	492 1.0×	543 1.2×	63	4.0k
Magali Terme France	25	2.4k 1.5×	2.5k 2.6×	1.3k 1.8×	672 1.4×	239 0.5×	51	4.4k
Valerie Chew Singapore	19	1.3k 0.8×	1.2k 1.3×	491 0.7×	367 0.7×	545 1.2×	37	2.4k
Francesco Galimi Italy	24	1.2k 0.7×	286 0.3×	1.1k 1.5×	458 0.9×	738 1.6×	35	2.5k
Zachary Boyd United States	14	2.3k 1.5×	1.2k 1.2×	1.1k 1.4×	731 1.5×	214 0.5×	27	3.7k
Yinghui Guan China	22	876 0.6×	469 0.5×	1.5k 2.0×	1.1k 2.3×	245 0.5×	54	2.6k

Countries citing papers authored by Mark D. McKee

Since Specialization

Citations

This map shows the geographic impact of Mark D. McKee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. McKee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. McKee more than expected).

Fields of papers citing papers by Mark D. McKee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. McKee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. McKee. The network helps show where Mark D. McKee may publish in the future.

Co-authorship network of co-authors of Mark D. McKee

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. McKee. A scholar is included among the top collaborators of Mark D. McKee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. McKee. Mark D. McKee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maitland, Michael L., Sarina A. Piha‐Paul, Gerald S. Falchook, et al.. (2018). Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. British Journal of Cancer. 118(8). 1042–1050. 18 indexed citations

Gray, Heidi J., Katherine M. Bell‐McGuinn, Gini F. Fleming, et al.. (2018). Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic Oncology. 148(3). 507–514. 58 indexed citations

Stinchcombe, Thomas E., David Kozono, Joseph K. Salama, et al.. (2017). MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC. Journal of Thoracic Oncology. 12(11). S1874–S1874. 1 indexed citations

Middleton, Mark R., Philip Friedlander, Omid Hamid, et al.. (2015). Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology. 26(10). 2173–2179. 69 indexed citations

O’Neil, Bert H., Călin Cainap, Eric Van Cutsem, et al.. (2014). Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 13(3). 156–163.e2. 17 indexed citations

Cainap, Călin, Shukui Qin, Wen‐Tsung Huang, et al.. (2014). Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 33(2). 172–179. 465 indexed citations breakdown →

Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2014). A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(5). S4–S5. 3 indexed citations

Harlin, Helena, Yuru Meng, Amy Peterson, et al.. (2009). Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment. Cancer Research. 69(7). 3077–3085. 872 indexed citations breakdown →

Klarquist, Jared, Sridhar Kandala, R. Braun, et al.. (2009). Melanoma-Associated Antigen Expression in Lymphangioleiomyomatosis Renders Tumor Cells Susceptible to Cytotoxic T Cells. American Journal Of Pathology. 175(6). 2463–2472. 26 indexed citations

10.

Hariharan, Vidhya, Jared Klarquist, Amy Koshoffer, et al.. (2009). Monobenzyl Ether of Hydroquinone and 4-Tertiary Butyl Phenol Activate Markedly Different Physiological Responses in Melanocytes: Relevance to Skin Depigmentation. Journal of Investigative Dermatology. 130(1). 211–220. 58 indexed citations

11.

Zureikat, Amer H. & Mark D. McKee. (2008). Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America. 17(2). 279–301. 9 indexed citations

12.

Miao, Haixi, et al.. (2007). Recognition of Carcinoembryonic Antigen Peptide and Heteroclitic Peptide by Peripheral Blood T Lymphocytes. Journal of Immunotherapy. 30(3). 350–358. 2 indexed citations

13.

Nishimura, Michael I., J. Roszkowski, Tamson V. Moore, et al.. (2007). Antigen Recognition and T-Cell Biology. Cancer treatment and research. 123. 37–59. 6 indexed citations

14.

Callender, Glenda G., Hugo R. Rosen, J. Roszkowski, et al.. (2006). Identification of a hepatitis C virus–reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology. 43(5). 973–981. 32 indexed citations

15.

McKee, Mark D., J. Roszkowski, & Michael I. Nishimura. (2005). T cell avidity and tumor recognition: implications and therapeutic strategies. Journal of Translational Medicine. 3(1). 35–35. 27 indexed citations

16.

Roszkowski, J., David C. Yu, Mark P. Rubinstein, et al.. (2003). CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell. The Journal of Immunology. 170(5). 2582–2589. 46 indexed citations

17.

McKee, Mark D., Stacey A. Cecco, Julie E. Niemela, et al.. (2002). Effects of interleukin 2 therapy on lymphocyte magnesium levels. Journal of Laboratory and Clinical Medicine. 139(1). 5–12. 3 indexed citations

18.

Clay, Timothy M., Mary Custer, Mark D. McKee, et al.. (1999). Changes in the Fine Specificity of gp100(209–217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue. The Journal of Immunology. 162(3). 1749–1755. 88 indexed citations

19.

McKee, Mark D., Timothy M. Clay, S A Rosenberg, & Michael I. Nishimura. (1999). Quantitation of T-Cell Receptor Frequencies by Competitive PCR: Generation and Evaluation of Novel TCR Subfamily and Clone Specific Competitors. Journal of Immunotherapy. 22(2). 93–102. 12 indexed citations

20.

Cormier, Janice N., James R. Vasselli, David Lee, et al.. (1997). A Prospective Randomized Evaluation of the Prophylactic Use of Low-Dose Dopamine in Cancer Patients Receiving Interleukin-2. Journal of Immunotherapy. 20(4). 292–300. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact